mardi 30 octobre 2018

Onco Actu du 30 octobre 2018

1. Biologie

Cancer’s Most Deadly Assassin Exists in Every Cell [Northwestern University]

1.4 Biologie - Technos

Pre-Existing Immunity to CRISPR Found in 96% of People in Study [Xconomy]

3.1.1 Prévention - Tabac - e-cigs

E-cigarette policy should consider environmental effects, expert says [Reuters]

3.3 Prévention - Vaccins

'Unprecedented' demand for Merck's Gardasil drives monster Q3 [FiercePharma]

4.12 Biopsies liquides

DNA Fragment End Analysis Could Improve Liquid Biopsy [Genome Web]

5.10 Traitements - Essais

Not so crystal clear: The EU’s clinical reporting problem [Pharmafile]

5.12.1 Immunothérapies - partenariats

MacroGenics and NanoString Enter Translational Research Collaboration to Identify and Develop Biomarkers in Immuno-Oncology [Nanostring]

5.12.2 Immunothérapies - CAR-T, thérapies cellulaires

The West is losing the gene editing race. It needs to catch up [STAT]

5.12.3 Immunothérapies-combinaisons

Combination immunotherapy yields high survival rate in advanced melanoma [Dana-Farber Cancer Institute]

5.2 Pharma

Johnson & Johnson down to its final Zytiga defenses as judge puts temporary kibosh on generics [FiercePharma]

Genmab Announces Positive Topline Results in Phase III MAIA Study of Daratumumab in Front Line Multiple Myeloma [Genmab]

6.12 Ethique

Should Failure to Disclose Significant Financial Conflicts of Interest Be Considered Research Misconduct? [JAMA]

6.5 Médecines alternatives/complémentaires

The Integrative Oncology Scholars Program: Indoctrinating oncology professionals into pseudoscience [Respectful Insolence]

6.7 DMP, Big Data & applis

On being and becoming a data science company [Novartis]

6.7.1 IA/bioinformatique

Truly, neurally, deeply [Knowable Magazine]

6.8 Communication

A step-by-step guide to creating health care clickbait [HealthNewsReview]